A carregar...
No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis
Whether tenofovir disoproxil fumarate (TDF) is superior to entecavir in reducing hepatocellular carcinoma (HCC) risk among treatment-naïve chronic hepatitis B (CHB) patients remains controversial. We aimed to clarify this controversy. Several databases, including PubMed and Embase, were retrieved th...
Na minha lista:
| Publicado no: | Aging (Albany NY) |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7993671/ https://ncbi.nlm.nih.gov/pubmed/33658397 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/aging.202573 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|